Pre-phase strategy to mitigate first cycle effect in diffuse large B cell lymphoma Article Swipe
A. H. Rudresha
,
Syed Adil Hassan
,
A. Sreevalli
,
D. Lokanatha
,
M. Babu
,
K.N. Lokesh
,
L K Rajeev
,
Smitha Saldanha
,
Antony George Francis Thottian
,
Kanika Sharma
,
Linu Abraham Jacob
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1186/s43046-022-00116-5
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1186/s43046-022-00116-5
Context Treatment-related toxicities in DLBCL (diffuse large B cell lymphoma) patients are higher in the initial phase of treatment (first cycle effect). Implementation of pre-phase treatment before definitive chemotherapy had been shown to alleviate some of these side-effects in a non-randomized study conducted earlier in our institute (Lakshmaiah et. al., Eur J Haematol 100:644-8, 2018). Aims This study was aimed at validating the role of pre-phase treatment in newly diagnosed DLBCL patients. Settings and design All newly diagnosed patients with DLBCL above the age of 18 years were evaluated for eligibility and prospectively enrolled. A single-arm prospective study was conducted at the Department of Medical Oncology, in our institute from July 2015 to December 2019. Methods and material Patients received vincristine and prednisolone as pre-phase treatment for 7 days after which definitive chemotherapy was instituted on day 1. They were followed up for 30 days post-first cycle chemotherapy. Statistical analysis used Paired Student’s t tests and Wilcoxon signed-ranks test were used for comparison of various clinical variables as appropriate. P value of less than 0.05 was considered significant. Results Among the 180 patients who were included in study, performance status improvement was noted in significant number of patients ( p < 0.001). 38.4% achieved an ECOG (Eastern Cooperative Oncology Group) performance status of 0 post-pre-phase therapy. Febrile neutropenia was observed in 12.8% in the present cohort as compared to the historical non-pre-phase cohort (34%). Conclusions Pre-phase therapy significantly improves the performance status and diminishes neutropenia rates in DLBCL patients.
Related Topics
Concepts
Medicine
Febrile neutropenia
Internal medicine
Neutropenia
Diffuse large B-cell lymphoma
Vincristine
Chemotherapy
Performance status
Prospective cohort study
Cohort
Prednisolone
Lymphoma
Oncology
Surgery
Cyclophosphamide
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1186/s43046-022-00116-5
- https://jenci.springeropen.com/track/pdf/10.1186/s43046-022-00116-5
- OA Status
- diamond
- Cited By
- 1
- References
- 8
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4229371027
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4229371027Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1186/s43046-022-00116-5Digital Object Identifier
- Title
-
Pre-phase strategy to mitigate first cycle effect in diffuse large B cell lymphomaWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-05-09Full publication date if available
- Authors
-
A. H. Rudresha, Syed Adil Hassan, A. Sreevalli, D. Lokanatha, M. Babu, K.N. Lokesh, L K Rajeev, Smitha Saldanha, Antony George Francis Thottian, Kanika Sharma, Linu Abraham JacobList of authors in order
- Landing page
-
https://doi.org/10.1186/s43046-022-00116-5Publisher landing page
- PDF URL
-
https://jenci.springeropen.com/track/pdf/10.1186/s43046-022-00116-5Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
diamondOpen access status per OpenAlex
- OA URL
-
https://jenci.springeropen.com/track/pdf/10.1186/s43046-022-00116-5Direct OA link when available
- Concepts
-
Medicine, Febrile neutropenia, Internal medicine, Neutropenia, Diffuse large B-cell lymphoma, Vincristine, Chemotherapy, Performance status, Prospective cohort study, Cohort, Prednisolone, Lymphoma, Oncology, Surgery, CyclophosphamideTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
1Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1Per-year citation counts (last 5 years)
- References (count)
-
8Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4229371027 |
|---|---|
| doi | https://doi.org/10.1186/s43046-022-00116-5 |
| ids.doi | https://doi.org/10.1186/s43046-022-00116-5 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/35527285 |
| ids.openalex | https://openalex.org/W4229371027 |
| fwci | 0.20727398 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000293 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Adolescent |
| mesh[1].qualifier_ui | Q000009 |
| mesh[1].descriptor_ui | D000971 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | adverse effects |
| mesh[1].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[2].qualifier_ui | Q000009 |
| mesh[2].descriptor_ui | D003520 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | adverse effects |
| mesh[2].descriptor_name | Cyclophosphamide |
| mesh[3].qualifier_ui | Q000627 |
| mesh[3].descriptor_ui | D004317 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | therapeutic use |
| mesh[3].descriptor_name | Doxorubicin |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D006801 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Humans |
| mesh[5].qualifier_ui | Q000188 |
| mesh[5].descriptor_ui | D016403 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | drug therapy |
| mesh[5].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[6].qualifier_ui | Q000009 |
| mesh[6].descriptor_ui | D011241 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | adverse effects |
| mesh[6].descriptor_name | Prednisone |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D011446 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Prospective Studies |
| mesh[8].qualifier_ui | Q000009 |
| mesh[8].descriptor_ui | D000069283 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | adverse effects |
| mesh[8].descriptor_name | Rituximab |
| mesh[9].qualifier_ui | Q000009 |
| mesh[9].descriptor_ui | D014750 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | adverse effects |
| mesh[9].descriptor_name | Vincristine |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D000293 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Adolescent |
| mesh[11].qualifier_ui | Q000009 |
| mesh[11].descriptor_ui | D000971 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | adverse effects |
| mesh[11].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[12].qualifier_ui | Q000009 |
| mesh[12].descriptor_ui | D003520 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | adverse effects |
| mesh[12].descriptor_name | Cyclophosphamide |
| mesh[13].qualifier_ui | Q000627 |
| mesh[13].descriptor_ui | D004317 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | therapeutic use |
| mesh[13].descriptor_name | Doxorubicin |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D006801 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Humans |
| mesh[15].qualifier_ui | Q000188 |
| mesh[15].descriptor_ui | D016403 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | drug therapy |
| mesh[15].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[16].qualifier_ui | Q000009 |
| mesh[16].descriptor_ui | D011241 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | adverse effects |
| mesh[16].descriptor_name | Prednisone |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D011446 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Prospective Studies |
| mesh[18].qualifier_ui | Q000009 |
| mesh[18].descriptor_ui | D000069283 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | adverse effects |
| mesh[18].descriptor_name | Rituximab |
| mesh[19].qualifier_ui | Q000009 |
| mesh[19].descriptor_ui | D014750 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | adverse effects |
| mesh[19].descriptor_name | Vincristine |
| type | article |
| title | Pre-phase strategy to mitigate first cycle effect in diffuse large B cell lymphoma |
| biblio.issue | 1 |
| biblio.volume | 34 |
| biblio.last_page | 20 |
| biblio.first_page | 20 |
| topics[0].id | https://openalex.org/T10185 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2734 |
| topics[0].subfield.display_name | Pathology and Forensic Medicine |
| topics[0].display_name | Lymphoma Diagnosis and Treatment |
| topics[1].id | https://openalex.org/T11157 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9994999766349792 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2716 |
| topics[1].subfield.display_name | Genetics |
| topics[1].display_name | Chronic Lymphocytic Leukemia Research |
| topics[2].id | https://openalex.org/T11491 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9991000294685364 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | CAR-T cell therapy research |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9233874082565308 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2778850193 |
| concepts[1].level | 4 |
| concepts[1].score | 0.6511735320091248 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q3775974 |
| concepts[1].display_name | Febrile neutropenia |
| concepts[2].id | https://openalex.org/C126322002 |
| concepts[2].level | 1 |
| concepts[2].score | 0.6396046280860901 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[2].display_name | Internal medicine |
| concepts[3].id | https://openalex.org/C2777063308 |
| concepts[3].level | 3 |
| concepts[3].score | 0.626284658908844 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1435822 |
| concepts[3].display_name | Neutropenia |
| concepts[4].id | https://openalex.org/C2778559949 |
| concepts[4].level | 3 |
| concepts[4].score | 0.6063780188560486 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q2626074 |
| concepts[4].display_name | Diffuse large B-cell lymphoma |
| concepts[5].id | https://openalex.org/C2779429289 |
| concepts[5].level | 4 |
| concepts[5].score | 0.5589305758476257 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q408977 |
| concepts[5].display_name | Vincristine |
| concepts[6].id | https://openalex.org/C2776694085 |
| concepts[6].level | 2 |
| concepts[6].score | 0.5362467169761658 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[6].display_name | Chemotherapy |
| concepts[7].id | https://openalex.org/C2776907518 |
| concepts[7].level | 3 |
| concepts[7].score | 0.5085045099258423 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1734165 |
| concepts[7].display_name | Performance status |
| concepts[8].id | https://openalex.org/C188816634 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4916308522224426 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q2113324 |
| concepts[8].display_name | Prospective cohort study |
| concepts[9].id | https://openalex.org/C72563966 |
| concepts[9].level | 2 |
| concepts[9].score | 0.48171287775039673 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1303415 |
| concepts[9].display_name | Cohort |
| concepts[10].id | https://openalex.org/C2776715498 |
| concepts[10].level | 2 |
| concepts[10].score | 0.4595682919025421 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q11426176 |
| concepts[10].display_name | Prednisolone |
| concepts[11].id | https://openalex.org/C2779338263 |
| concepts[11].level | 2 |
| concepts[11].score | 0.42998653650283813 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q208414 |
| concepts[11].display_name | Lymphoma |
| concepts[12].id | https://openalex.org/C143998085 |
| concepts[12].level | 1 |
| concepts[12].score | 0.34689342975616455 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[12].display_name | Oncology |
| concepts[13].id | https://openalex.org/C141071460 |
| concepts[13].level | 1 |
| concepts[13].score | 0.33341845870018005 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q40821 |
| concepts[13].display_name | Surgery |
| concepts[14].id | https://openalex.org/C2776755627 |
| concepts[14].level | 3 |
| concepts[14].score | 0.19566601514816284 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q408524 |
| concepts[14].display_name | Cyclophosphamide |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9233874082565308 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/febrile-neutropenia |
| keywords[1].score | 0.6511735320091248 |
| keywords[1].display_name | Febrile neutropenia |
| keywords[2].id | https://openalex.org/keywords/internal-medicine |
| keywords[2].score | 0.6396046280860901 |
| keywords[2].display_name | Internal medicine |
| keywords[3].id | https://openalex.org/keywords/neutropenia |
| keywords[3].score | 0.626284658908844 |
| keywords[3].display_name | Neutropenia |
| keywords[4].id | https://openalex.org/keywords/diffuse-large-b-cell-lymphoma |
| keywords[4].score | 0.6063780188560486 |
| keywords[4].display_name | Diffuse large B-cell lymphoma |
| keywords[5].id | https://openalex.org/keywords/vincristine |
| keywords[5].score | 0.5589305758476257 |
| keywords[5].display_name | Vincristine |
| keywords[6].id | https://openalex.org/keywords/chemotherapy |
| keywords[6].score | 0.5362467169761658 |
| keywords[6].display_name | Chemotherapy |
| keywords[7].id | https://openalex.org/keywords/performance-status |
| keywords[7].score | 0.5085045099258423 |
| keywords[7].display_name | Performance status |
| keywords[8].id | https://openalex.org/keywords/prospective-cohort-study |
| keywords[8].score | 0.4916308522224426 |
| keywords[8].display_name | Prospective cohort study |
| keywords[9].id | https://openalex.org/keywords/cohort |
| keywords[9].score | 0.48171287775039673 |
| keywords[9].display_name | Cohort |
| keywords[10].id | https://openalex.org/keywords/prednisolone |
| keywords[10].score | 0.4595682919025421 |
| keywords[10].display_name | Prednisolone |
| keywords[11].id | https://openalex.org/keywords/lymphoma |
| keywords[11].score | 0.42998653650283813 |
| keywords[11].display_name | Lymphoma |
| keywords[12].id | https://openalex.org/keywords/oncology |
| keywords[12].score | 0.34689342975616455 |
| keywords[12].display_name | Oncology |
| keywords[13].id | https://openalex.org/keywords/surgery |
| keywords[13].score | 0.33341845870018005 |
| keywords[13].display_name | Surgery |
| keywords[14].id | https://openalex.org/keywords/cyclophosphamide |
| keywords[14].score | 0.19566601514816284 |
| keywords[14].display_name | Cyclophosphamide |
| language | en |
| locations[0].id | doi:10.1186/s43046-022-00116-5 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210209315 |
| locations[0].source.issn | 1110-0362, 2589-0409 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1110-0362 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Journal of the Egyptian National Cancer Institute |
| locations[0].source.host_organization | https://openalex.org/P4310319965 |
| locations[0].source.host_organization_name | Springer Nature |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310319965 |
| locations[0].source.host_organization_lineage_names | Springer Nature |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://jenci.springeropen.com/track/pdf/10.1186/s43046-022-00116-5 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Journal of the Egyptian National Cancer Institute |
| locations[0].landing_page_url | https://doi.org/10.1186/s43046-022-00116-5 |
| locations[1].id | pmid:35527285 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Journal of the Egyptian National Cancer Institute |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/35527285 |
| locations[2].id | pmh:oai:doaj.org/article:c902ba2e39e84dd6b0fcdcef06ac5223 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Journal of the Egyptian National Cancer Institute, Vol 34, Iss 1, Pp 1-5 (2022) |
| locations[2].landing_page_url | https://doaj.org/article/c902ba2e39e84dd6b0fcdcef06ac5223 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5057997548 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | A. H. Rudresha |
| authorships[0].countries | IN |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I2802933311 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[0].institutions[0].id | https://openalex.org/I2802933311 |
| authorships[0].institutions[0].ror | https://ror.org/027h1w574 |
| authorships[0].institutions[0].type | facility |
| authorships[0].institutions[0].lineage | https://openalex.org/I2802933311 |
| authorships[0].institutions[0].country_code | IN |
| authorships[0].institutions[0].display_name | Kidwai Memorial Institute of Oncology |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | A. H. Rudresha |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[1].author.id | https://openalex.org/A5112530973 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Syed Adil Hassan |
| authorships[1].countries | IN |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I2802933311 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[1].institutions[0].id | https://openalex.org/I2802933311 |
| authorships[1].institutions[0].ror | https://ror.org/027h1w574 |
| authorships[1].institutions[0].type | facility |
| authorships[1].institutions[0].lineage | https://openalex.org/I2802933311 |
| authorships[1].institutions[0].country_code | IN |
| authorships[1].institutions[0].display_name | Kidwai Memorial Institute of Oncology |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Syed Adil Hassan |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[2].author.id | https://openalex.org/A5081556657 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | A. Sreevalli |
| authorships[2].countries | IN |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I2802933311 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[2].institutions[0].id | https://openalex.org/I2802933311 |
| authorships[2].institutions[0].ror | https://ror.org/027h1w574 |
| authorships[2].institutions[0].type | facility |
| authorships[2].institutions[0].lineage | https://openalex.org/I2802933311 |
| authorships[2].institutions[0].country_code | IN |
| authorships[2].institutions[0].display_name | Kidwai Memorial Institute of Oncology |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | A. Sreevalli |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[3].author.id | https://openalex.org/A5112477769 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | D. Lokanatha |
| authorships[3].countries | IN |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I2802933311 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[3].institutions[0].id | https://openalex.org/I2802933311 |
| authorships[3].institutions[0].ror | https://ror.org/027h1w574 |
| authorships[3].institutions[0].type | facility |
| authorships[3].institutions[0].lineage | https://openalex.org/I2802933311 |
| authorships[3].institutions[0].country_code | IN |
| authorships[3].institutions[0].display_name | Kidwai Memorial Institute of Oncology |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | D. Lokanatha |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[4].author.id | https://openalex.org/A5087029592 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-1497-9489 |
| authorships[4].author.display_name | M. Babu |
| authorships[4].countries | IN |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I2802933311 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[4].institutions[0].id | https://openalex.org/I2802933311 |
| authorships[4].institutions[0].ror | https://ror.org/027h1w574 |
| authorships[4].institutions[0].type | facility |
| authorships[4].institutions[0].lineage | https://openalex.org/I2802933311 |
| authorships[4].institutions[0].country_code | IN |
| authorships[4].institutions[0].display_name | Kidwai Memorial Institute of Oncology |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | M. C. Suresh Babu |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[5].author.id | https://openalex.org/A5013785261 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | K.N. Lokesh |
| authorships[5].countries | IN |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I2802933311 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[5].institutions[0].id | https://openalex.org/I2802933311 |
| authorships[5].institutions[0].ror | https://ror.org/027h1w574 |
| authorships[5].institutions[0].type | facility |
| authorships[5].institutions[0].lineage | https://openalex.org/I2802933311 |
| authorships[5].institutions[0].country_code | IN |
| authorships[5].institutions[0].display_name | Kidwai Memorial Institute of Oncology |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | K. N. Lokesh |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[6].author.id | https://openalex.org/A5113938785 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | L K Rajeev |
| authorships[6].countries | IN |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I2802933311 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[6].institutions[0].id | https://openalex.org/I2802933311 |
| authorships[6].institutions[0].ror | https://ror.org/027h1w574 |
| authorships[6].institutions[0].type | facility |
| authorships[6].institutions[0].lineage | https://openalex.org/I2802933311 |
| authorships[6].institutions[0].country_code | IN |
| authorships[6].institutions[0].display_name | Kidwai Memorial Institute of Oncology |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | L. K. Rajeev |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[7].author.id | https://openalex.org/A5014155783 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-8298-0705 |
| authorships[7].author.display_name | Smitha Saldanha |
| authorships[7].countries | IN |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I2802933311 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[7].institutions[0].id | https://openalex.org/I2802933311 |
| authorships[7].institutions[0].ror | https://ror.org/027h1w574 |
| authorships[7].institutions[0].type | facility |
| authorships[7].institutions[0].lineage | https://openalex.org/I2802933311 |
| authorships[7].institutions[0].country_code | IN |
| authorships[7].institutions[0].display_name | Kidwai Memorial Institute of Oncology |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Smitha Saldanha |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[8].author.id | https://openalex.org/A5087749492 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-2666-4561 |
| authorships[8].author.display_name | Antony George Francis Thottian |
| authorships[8].countries | IN |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I2802933311 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[8].institutions[0].id | https://openalex.org/I2802933311 |
| authorships[8].institutions[0].ror | https://ror.org/027h1w574 |
| authorships[8].institutions[0].type | facility |
| authorships[8].institutions[0].lineage | https://openalex.org/I2802933311 |
| authorships[8].institutions[0].country_code | IN |
| authorships[8].institutions[0].display_name | Kidwai Memorial Institute of Oncology |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Antony G. F. Thottian |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[9].author.id | https://openalex.org/A5080902352 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-1256-4626 |
| authorships[9].author.display_name | Kanika Sharma |
| authorships[9].countries | IN |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I2802933311 |
| authorships[9].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[9].institutions[0].id | https://openalex.org/I2802933311 |
| authorships[9].institutions[0].ror | https://ror.org/027h1w574 |
| authorships[9].institutions[0].type | facility |
| authorships[9].institutions[0].lineage | https://openalex.org/I2802933311 |
| authorships[9].institutions[0].country_code | IN |
| authorships[9].institutions[0].display_name | Kidwai Memorial Institute of Oncology |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Kanika Sharma |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[10].author.id | https://openalex.org/A5049312262 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-5806-1004 |
| authorships[10].author.display_name | Linu Abraham Jacob |
| authorships[10].countries | IN |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I2802933311 |
| authorships[10].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| authorships[10].institutions[0].id | https://openalex.org/I2802933311 |
| authorships[10].institutions[0].ror | https://ror.org/027h1w574 |
| authorships[10].institutions[0].type | facility |
| authorships[10].institutions[0].lineage | https://openalex.org/I2802933311 |
| authorships[10].institutions[0].country_code | IN |
| authorships[10].institutions[0].display_name | Kidwai Memorial Institute of Oncology |
| authorships[10].author_position | last |
| authorships[10].raw_author_name | Linu Abraham Jacob |
| authorships[10].is_corresponding | True |
| authorships[10].raw_affiliation_strings | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://jenci.springeropen.com/track/pdf/10.1186/s43046-022-00116-5 |
| open_access.oa_status | diamond |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Pre-phase strategy to mitigate first cycle effect in diffuse large B cell lymphoma |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10185 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2734 |
| primary_topic.subfield.display_name | Pathology and Forensic Medicine |
| primary_topic.display_name | Lymphoma Diagnosis and Treatment |
| related_works | https://openalex.org/W2412912370, https://openalex.org/W1196768483, https://openalex.org/W2079621758, https://openalex.org/W4229917508, https://openalex.org/W2102925359, https://openalex.org/W2128269008, https://openalex.org/W4311331895, https://openalex.org/W2791017441, https://openalex.org/W2418393430, https://openalex.org/W2991935874 |
| cited_by_count | 1 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1186/s43046-022-00116-5 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210209315 |
| best_oa_location.source.issn | 1110-0362, 2589-0409 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1110-0362 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Journal of the Egyptian National Cancer Institute |
| best_oa_location.source.host_organization | https://openalex.org/P4310319965 |
| best_oa_location.source.host_organization_name | Springer Nature |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310319965 |
| best_oa_location.source.host_organization_lineage_names | Springer Nature |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://jenci.springeropen.com/track/pdf/10.1186/s43046-022-00116-5 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Journal of the Egyptian National Cancer Institute |
| best_oa_location.landing_page_url | https://doi.org/10.1186/s43046-022-00116-5 |
| primary_location.id | doi:10.1186/s43046-022-00116-5 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210209315 |
| primary_location.source.issn | 1110-0362, 2589-0409 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1110-0362 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Journal of the Egyptian National Cancer Institute |
| primary_location.source.host_organization | https://openalex.org/P4310319965 |
| primary_location.source.host_organization_name | Springer Nature |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310319965 |
| primary_location.source.host_organization_lineage_names | Springer Nature |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://jenci.springeropen.com/track/pdf/10.1186/s43046-022-00116-5 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Journal of the Egyptian National Cancer Institute |
| primary_location.landing_page_url | https://doi.org/10.1186/s43046-022-00116-5 |
| publication_date | 2022-05-09 |
| publication_year | 2022 |
| referenced_works | https://openalex.org/W1969582706, https://openalex.org/W2108465006, https://openalex.org/W1993815556, https://openalex.org/W2791302770, https://openalex.org/W2150852418, https://openalex.org/W2600153453, https://openalex.org/W2106928992, https://openalex.org/W2622375091 |
| referenced_works_count | 8 |
| abstract_inverted_index.( | 199 |
| abstract_inverted_index.0 | 214 |
| abstract_inverted_index.7 | 128 |
| abstract_inverted_index.A | 95 |
| abstract_inverted_index.B | 8 |
| abstract_inverted_index.J | 52 |
| abstract_inverted_index.P | 170 |
| abstract_inverted_index.a | 40 |
| abstract_inverted_index.p | 200 |
| abstract_inverted_index.t | 154 |
| abstract_inverted_index.1. | 138 |
| abstract_inverted_index.18 | 86 |
| abstract_inverted_index.30 | 144 |
| abstract_inverted_index.an | 205 |
| abstract_inverted_index.as | 124, 168, 227 |
| abstract_inverted_index.at | 61, 101 |
| abstract_inverted_index.in | 4, 14, 39, 45, 68, 107, 187, 194, 221, 223, 247 |
| abstract_inverted_index.of | 18, 24, 36, 65, 85, 104, 164, 172, 197, 213 |
| abstract_inverted_index.on | 136 |
| abstract_inverted_index.to | 33, 113, 229 |
| abstract_inverted_index.up | 142 |
| abstract_inverted_index.180 | 182 |
| abstract_inverted_index.All | 76 |
| abstract_inverted_index.Eur | 51 |
| abstract_inverted_index.age | 84 |
| abstract_inverted_index.and | 74, 92, 117, 122, 156, 243 |
| abstract_inverted_index.are | 12 |
| abstract_inverted_index.day | 137 |
| abstract_inverted_index.et. | 49 |
| abstract_inverted_index.for | 90, 127, 143, 162 |
| abstract_inverted_index.had | 30 |
| abstract_inverted_index.our | 46, 108 |
| abstract_inverted_index.the | 15, 63, 83, 102, 181, 224, 230, 240 |
| abstract_inverted_index.was | 59, 99, 134, 176, 192, 219 |
| abstract_inverted_index.who | 184 |
| abstract_inverted_index.< | 201 |
| abstract_inverted_index.0.05 | 175 |
| abstract_inverted_index.2015 | 112 |
| abstract_inverted_index.Aims | 56 |
| abstract_inverted_index.ECOG | 206 |
| abstract_inverted_index.July | 111 |
| abstract_inverted_index.They | 139 |
| abstract_inverted_index.This | 57 |
| abstract_inverted_index.al., | 50 |
| abstract_inverted_index.been | 31 |
| abstract_inverted_index.cell | 9 |
| abstract_inverted_index.days | 129, 145 |
| abstract_inverted_index.from | 110 |
| abstract_inverted_index.less | 173 |
| abstract_inverted_index.role | 64 |
| abstract_inverted_index.some | 35 |
| abstract_inverted_index.test | 159 |
| abstract_inverted_index.than | 174 |
| abstract_inverted_index.used | 151, 161 |
| abstract_inverted_index.were | 88, 140, 160, 185 |
| abstract_inverted_index.with | 80 |
| abstract_inverted_index.12.8% | 222 |
| abstract_inverted_index.2019. | 115 |
| abstract_inverted_index.38.4% | 203 |
| abstract_inverted_index.Among | 180 |
| abstract_inverted_index.DLBCL | 5, 71, 81, 248 |
| abstract_inverted_index.above | 82 |
| abstract_inverted_index.after | 130 |
| abstract_inverted_index.aimed | 60 |
| abstract_inverted_index.cycle | 21, 147 |
| abstract_inverted_index.large | 7 |
| abstract_inverted_index.newly | 69, 77 |
| abstract_inverted_index.noted | 193 |
| abstract_inverted_index.phase | 17 |
| abstract_inverted_index.rates | 246 |
| abstract_inverted_index.shown | 32 |
| abstract_inverted_index.study | 42, 58, 98 |
| abstract_inverted_index.tests | 155 |
| abstract_inverted_index.these | 37 |
| abstract_inverted_index.value | 171 |
| abstract_inverted_index.which | 131 |
| abstract_inverted_index.years | 87 |
| abstract_inverted_index.(34%). | 234 |
| abstract_inverted_index.(first | 20 |
| abstract_inverted_index.2018). | 55 |
| abstract_inverted_index.Group) | 210 |
| abstract_inverted_index.Paired | 152 |
| abstract_inverted_index.before | 27 |
| abstract_inverted_index.cohort | 226, 233 |
| abstract_inverted_index.design | 75 |
| abstract_inverted_index.higher | 13 |
| abstract_inverted_index.number | 196 |
| abstract_inverted_index.status | 190, 212, 242 |
| abstract_inverted_index.study, | 188 |
| abstract_inverted_index.0.001). | 202 |
| abstract_inverted_index.Context | 1 |
| abstract_inverted_index.Febrile | 217 |
| abstract_inverted_index.Medical | 105 |
| abstract_inverted_index.Methods | 116 |
| abstract_inverted_index.Results | 179 |
| abstract_inverted_index.earlier | 44 |
| abstract_inverted_index.initial | 16 |
| abstract_inverted_index.present | 225 |
| abstract_inverted_index.therapy | 237 |
| abstract_inverted_index.various | 165 |
| abstract_inverted_index.(Eastern | 207 |
| abstract_inverted_index.(diffuse | 6 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.December | 114 |
| abstract_inverted_index.Haematol | 53 |
| abstract_inverted_index.Oncology | 209 |
| abstract_inverted_index.Patients | 119 |
| abstract_inverted_index.Settings | 73 |
| abstract_inverted_index.Wilcoxon | 157 |
| abstract_inverted_index.achieved | 204 |
| abstract_inverted_index.analysis | 150 |
| abstract_inverted_index.clinical | 166 |
| abstract_inverted_index.compared | 228 |
| abstract_inverted_index.effect). | 22 |
| abstract_inverted_index.followed | 141 |
| abstract_inverted_index.improves | 239 |
| abstract_inverted_index.included | 186 |
| abstract_inverted_index.material | 118 |
| abstract_inverted_index.observed | 220 |
| abstract_inverted_index.patients | 11, 79, 183, 198 |
| abstract_inverted_index.received | 120 |
| abstract_inverted_index.therapy. | 216 |
| abstract_inverted_index.Oncology, | 106 |
| abstract_inverted_index.Pre-phase | 236 |
| abstract_inverted_index.alleviate | 34 |
| abstract_inverted_index.conducted | 43, 100 |
| abstract_inverted_index.diagnosed | 70, 78 |
| abstract_inverted_index.enrolled. | 94 |
| abstract_inverted_index.evaluated | 89 |
| abstract_inverted_index.institute | 47, 109 |
| abstract_inverted_index.lymphoma) | 10 |
| abstract_inverted_index.patients. | 72, 249 |
| abstract_inverted_index.pre-phase | 25, 66, 125 |
| abstract_inverted_index.treatment | 19, 26, 67, 126 |
| abstract_inverted_index.variables | 167 |
| abstract_inverted_index.100:644-8, | 54 |
| abstract_inverted_index.Department | 103 |
| abstract_inverted_index.comparison | 163 |
| abstract_inverted_index.considered | 177 |
| abstract_inverted_index.definitive | 28, 132 |
| abstract_inverted_index.diminishes | 244 |
| abstract_inverted_index.historical | 231 |
| abstract_inverted_index.instituted | 135 |
| abstract_inverted_index.post-first | 146 |
| abstract_inverted_index.single-arm | 96 |
| abstract_inverted_index.toxicities | 3 |
| abstract_inverted_index.validating | 62 |
| abstract_inverted_index.(Lakshmaiah | 48 |
| abstract_inverted_index.Conclusions | 235 |
| abstract_inverted_index.Cooperative | 208 |
| abstract_inverted_index.Statistical | 149 |
| abstract_inverted_index.Student’s | 153 |
| abstract_inverted_index.eligibility | 91 |
| abstract_inverted_index.improvement | 191 |
| abstract_inverted_index.neutropenia | 218, 245 |
| abstract_inverted_index.performance | 189, 211, 241 |
| abstract_inverted_index.prospective | 97 |
| abstract_inverted_index.significant | 195 |
| abstract_inverted_index.vincristine | 121 |
| abstract_inverted_index.appropriate. | 169 |
| abstract_inverted_index.chemotherapy | 29, 133 |
| abstract_inverted_index.prednisolone | 123 |
| abstract_inverted_index.side-effects | 38 |
| abstract_inverted_index.signed-ranks | 158 |
| abstract_inverted_index.significant. | 178 |
| abstract_inverted_index.chemotherapy. | 148 |
| abstract_inverted_index.non-pre-phase | 232 |
| abstract_inverted_index.prospectively | 93 |
| abstract_inverted_index.significantly | 238 |
| abstract_inverted_index.Implementation | 23 |
| abstract_inverted_index.non-randomized | 41 |
| abstract_inverted_index.post-pre-phase | 215 |
| abstract_inverted_index.Treatment-related | 2 |
| cited_by_percentile_year.max | 95 |
| cited_by_percentile_year.min | 91 |
| corresponding_author_ids | https://openalex.org/A5049312262 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 11 |
| corresponding_institution_ids | https://openalex.org/I2802933311 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.6200000047683716 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.46011729 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |